NCT02348203View on ClinicalTrials.gov

Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 13, 2016

Primary Completion Date

February 22, 2019

Study Completion Date

March 9, 2021

Conditions
Tobacco Use Disorder
Interventions
DRUG

Aspirin

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Placebo Administration

Given aspirin placebo PO

OTHER

Placebo Administration

Given zileuton placebo PO

DRUG

Zileuton

Given PO

Trial Locations (2)

85719

Banner University Medical Center - Tucson, Tucson

02118

Boston University School of Medicine, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02348203 - Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers | Biotech Hunter | Biotech Hunter